stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) EV/Sales
As of 5 November 2026, IDEAYA Biosciences, Inc. (IDYA) trades at a EV/Sales of 63.7×. Over the past ten years it has ranged from 0.0× (June 2021) to 114× (July 2024); the current reading is higher than 85% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.5× | (82.76%) |
| FY2024 | 60.8× | (5.19%) |
| FY2023 | 64.2× | 819.46% |
| FY2022 | 7.0× | (66.75%) |
| FY2021 | 21.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 85.3× | 667.51% |
| Jun 2026 | 11.1× | 11.52% |
| Mar 2026 | 10.0× | (4.98%) |
| Dec 2025 | 10.5× | 44.43% |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| CELC Celcuity, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.2× |
| BEAM Beam Therapeutics Inc. compare | 12.2× |
| IDYA IDEAYA Biosciences, Inc. | 63.7× |
| VRDN Viridian Therapeutics, Inc. compare | 91.0× |
| DNLI Denali Therapeutics Inc. compare | 143× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement